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Chemical chaperonesMultidrug resistance protein 1 (MRP1) extrudes drugs as well as pharmacologically and physiologically impor-
tant organic anions across the plasma membrane in an ATP-dependent manner. We previously showed that
Ala substitutions of Lys513 and Lys516 in the cytoplasmic loop (CL5) connecting transmembrane helix 9 (TM9)
to TM10 causemisfolding ofMRP1, abrogating its expression at the plasmamembrane in transfected human em-
bryonic kidney (HEK) cells. Exposure of HEK cells to the chemical chaperones glycerol, DMSO, polyethylene gly-
col (PEG) and 4-aminobutyric acid (4-PBA) improved levels of K513A to wild-type MRP1 levels but transport
activity was only fully restored by 4-PBA or DMSO treatments. Tryptic fragmentation patterns and
conformation-dependent antibody immunoreactivity of the transport-deﬁcient PEG- and glycerol-rescued
K513A proteins indicated that the second nucleotide binding domain (NBD2) had adopted a more open confor-
mation than in wild-type MRP1. This structural change was accompanied by differences in ATP binding and hy-
drolysis but no changes in substrate Km. In contrast to K513A, K516A levels in HEK cells were not signiﬁcantly
enhanced by chemical chaperones. In more permissive insect cells, however, K516A levels were comparable to
wild-type MRP1. Nevertheless, organic anion transport by K516A in insect cell membranes was reduced by
N80% due to reduced substrate Km. Tryptic fragmentation patterns indicated a more open conformation of the
third membrane spanning domain of MRP1. Thus, despite their close proximity to one another in CL5, Lys513
and Lys516 participate in different interdomain interactions crucial for the proper folding and assembly of MRP1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Multidrug resistance protein 1 (MRP1) is an ATP-binding cassette
(ABC) transporter thatmediates the ATP-dependent efﬂux of awide va-
riety of structurally diverse compounds across the plasma membrane.
Among the nine drug transporters within the ‘C’ sub-family of the ABC
superfamily, MRP1 (ABCC1) is themost commonly associatedwith clin-
ical multidrug resistance, a major cause of failure of chemotherapy in
cancer patients. In addition to anticancer agents, MRP1 mediates the
ATP-dependent efﬂux of a variety of organic anions that include both-binding cassette; CL, cytoplas-
ce protein 1; MSD, membrane
, polyethylene glycol; TBS, Tris-
ine-N-oxide
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ights reserved.endogenous metabolites and exogenous xenobiotics, many of which
are conjugated to glutathione (e.g. the cysteinyl leukotriene C4 (LTC4))
or glucuronide (e.g. estradiol glucuronide, (E217βG)) [1–3]. It also
transports both the reduced and the oxidized forms of glutathione
(GSH) and thus contributes to the many physiological and pathological
processes inﬂuenced by these small peptides, including oxidative stress
[2,4].
The functional core structure of MRP1, like most ABC proteins, con-
sists of two membrane spanning domains (MSD1 and MSD2) and two
nucleotide binding domains (NBD1 andNBD2)which bind ATP and cat-
alyze its hydrolysis to provide the energy necessary for the transport
process [5]. Several ABCC subfamily members, including MRP1, have
an additional, third MSD (MSD0) that precedes the four domain core
structure (Fig. 1A) [3,6]. The transmembrane (TM) α-helices of MSD1
and MSD2 form the substrate translocation pathway and are brought
into proximity to the NBDs through the cytoplasmic (or luminal)
loops (CLs) that connect the TMs (Fig. 1B) [7].
Our recent studies have focused on understanding the functional
role played by the cytoplasmic loop (CL5) that connects TM9 to TM10
in MSD1 of MRP1. CL5 contains a high density of charged residues,
some of which are critically important for both the expression and the
Fig. 1. Secondary structure and homologymodels of MRP1. (A) Shown is a predicted secondary structure of MRP1 indicating the sites of N-glycosylation, the location of K513 and K516 in
CL5, and the epitopes detected by themAbs used in this study. (B) Three-dimensional homologymodel of MRP1 (lackingMSD0) generated using the crystal structure of nucleotide bound
S. aureus Sav1866 as template and created using PyMOL [48]; expanded on the right is the region of MRP1 with the predicted location of Lys513 and Lys516 (blue) in the coupling helix of
CL5 at the interface with NBD2; and Glu521 (red) in the α-helix ascending toward the plasma membrane. CL5 (green); MSD1 and NBD1 (cyan); MSD2 and NBD2 (magenta).
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caused a signiﬁcant reduction in organic anion transport activity while
Ala substitution of Lys513, Lys516, Glu521 or Glu535 abrogated MRP1 ex-
pression by disrupting the folding and assembly of the transporter,
targeting it for degradation by the proteasome [8,9].
In the case of three of these misfolded CL5 mutants (K513A, E521A
and E535A), plasmamembraneMRP1 levels could be improved signiﬁ-
cantly by exposing transfected HEK cells to the widely used chemical
chaperone, 4-phenylbutyric acid (4-PBA) [9,10]. Although the 4-PBA-
rescued E521A and E535Amutants were stably expressed, they exhibit-
ed mechanistically distinct transport deﬁciencies that were associated
with different structural conformations of the transporter that in turn
indicated that the folding and assembly processes for MRP1 are distinct
from those of its homolog CFTR [9].
In contrast to E521A and E535A, the 4-PBA rescued K513A mu-
tant exhibited transport properties comparable to wild-type MRP1.
Consequently, the failure of 4-PBA to rescue expression of the fourth
processing mutant, K516A, was unexpected, particularly since
Lys516 is within one turn of Lys513 in the same α-helix (the so-
called coupling α-helix) that atomic homology models predict
runs roughly parallel to the plasma membrane and interfaces with
NBD1 and NBD2 [7,8]. In the present study, we have further investi-
gated the relative abilities of several chemical chaperones to rescue
the expression and/or function of K513A and K516A to better under-
stand the distinct roles that Lys513 and Lys516 play in promoting the
proper folding and assembly of MRP1, and its trafﬁcking to the plas-
ma membrane.2. Materials and methods
2.1. Materials
[14,15,19,20-3H]LTC4 (158 Ci mmol−1) and [6,7-3H]E217βG
(45 Ci mmol−1) were purchased from PerkinElmer Life and
Analytical Sciences (Woodbridge, ON, Canada). 8-Azido-[α-32P]
ATP (3.7 Ci mmol−1) was from Afﬁnity Photoprobes (Lexington, KY).
LTC4 was purchased from Calbiochem (San Diego, CA) and E217βG, nu-
cleotides, DMSO, PEG (polyethylene glycol 400), trimethylamine-N-
oxide (TMAO), 4-PBA, proline, apigenin, diphenylcarbamyl chloride-
treated trypsin, sodium orthovanadate, and DAPI were purchased
from Sigma (Oakville, ON, Canada). The MRP1-speciﬁc mAb 897.2
was a kind gift from Dr. X.B. Chang (Mayo Clinic College of Medicine,
Scottsdale, AZ) [11]; murine mAb MRPm6, and rat mAb MRPr1 were
kind gifts fromDrs. R.J. Scheper and G.L. Scheffer (VU UniversityMedical
Center, Amsterdam, NL) [12]; and murine mAbs QCRL-1, QCRL-2 and
QCRL-4 were generated and characterized in this laboratory [13–15].
Antibodies against calnexin Na+/K+-ATPase (rabbit polyclonal) and α-
tubulin (murine mAb IgG) were from Santa Cruz Biotechnology and
Sigma Aldrich, respectively.
2.2. Preparation of MRP1-enrichedmembrane vesicles andmeasurement of
MRP1 levels in HEK293T and Sf9 insect cells
The generation of wild-type, K513A and K516A mutant MRP1
pcDNA3.1 expression vectors has been described previously [8,16].
758 S.H. Iram, S.P.C. Cole / Biochimica et Biophysica Acta 1838 (2014) 756–765The vectors (20 μg DNA)were transfected into 90–95% conﬂuent SV40-
transformedhumanembryonic kidney cells (HEK293T)using Lipofecta-
mine 2000 (75 μl) (Invitrogen, Carlsbad, CA). Cells were typically
collected after 48 h andmembrane vesicles prepared and protein levels
determined as before [16].
Wild-type and K516A mutant MRP1 were also cloned into
pFastBac vectors (Life Technologies Inc.) for expression in Sf9 insect
cells. A 4.7-kb XbaI/KpnI MRP1 fragment was subcloned from the
pcDNA3.1 vectors into pFastBac and the sequence integrity con-
ﬁrmed. Recombinant bacmids and baculoviruses were generated as
described previously [17]. Sf9 cells were grown in Grace's insect
cell medium supplemented with tryptose broth (2 g l−1) and 10%
fetal bovine serum. Sf9 cells grown as monolayers were infected
at 80% conﬂuency with 1.25 ml of wild-type or K516A MRP1
baculoviruses (8 × 107 IFU ml−1) per 150 mm plate. Cells were col-
lected after 72 h and membrane vesicles prepared and protein
quantiﬁed as before.2.3. Detection of MRP1 in HEK293T and Sf9 insect cells
Levels ofmutant andwild-typeMRP1were determined by immuno-
blot analysis using mAb QCRL-1 (IgG1; diluted 1:5000–10,000) [14]. To
conﬁrm equal loading of protein, blots were stained with amido black
and/or probed with antibodies against α-tubulin (diluted 1:20,000)
(for whole cell lysates) or Na+/K+-ATPase (diluted 1:1000) (for mem-
brane vesicles). Primary antibody binding was visualized by enhanced
chemiluminescence detection using appropriate horseradish peroxi-
dase conjugated secondary antibodies. Densitometry of immunoblots
was performed using ImageJ software (http://rsb.info.nih.gov/ij/).
Non-denaturing dot blots of HEK293Tmembrane vesicles were per-
formed using a 96-well manifold to load 0.5, 1.0 and 2 μg of membrane
vesicle protein on a membrane in 100 μl Tris-buffered saline (TBS) per
well [15,18]. After washing twice with TBS containing 0.05% Tween
20, the dot blot was removed from the manifold, blocked and probed
with mAb QCRL-2 (diluted 1:1000) or mAb QCRL-4 (diluted 1:1000)
which detect conformation-dependent epitopes of MRP1 contained
within NBD1 (amino acids 617–858) and NBD2 (amino acids
1294–1531), respectively [13,15], followed by horseradish peroxidase
conjugated secondary antibody and chemiluminescence detection as
before. Equal protein loading of the dot blots was conﬁrmed by amido
black staining. Relative levels of MRP1 proteins were estimated by den-
sitometry as before.2.4. MRP1-mediated uptake of 3H-labeled substrates into membrane
vesicles
ATP-dependent uptake of 3H-labeled organic anion substrates by
the membrane vesicles was measured using a 96-well plate rapid
ﬁltration method [8,19]. In brief, 2 μg of membrane vesicle protein
was incubated with 50 nM/10 nCi [3H]LTC4 for 45 s or 1 min at 23 °C
or 400 nM/20 nCi [3H]E217βG for 1 min at 37 °C, with 10 mMMgCl2,
2 mM AMP or 2 mM ATP, in transport buffer (250 mM sucrose,
50 mM Tris–HCl, pH 7.4). Uptake was stopped by rapid dilution, reac-
tionsﬁltered, and then tritiumassociatedwith the vesicleswas counted.
ATP-dependent uptake was calculated by subtracting uptake in the
presence of AMP from uptake in the presence of ATP. Transport assays
were carried out in duplicate or triplicate, and results expressed as
means and corrected to take into account any differences in levels of
mutant MRP1 relative to wild-type MRP1. Kinetic parameters for
E217βG uptake by HEK293T membrane vesicles were determined by
measuring ATP-dependent uptake at eight different E217βG concentra-
tions (range 0.25–25 μM), and Km and Vmax values calculated by non-
linear regression and Michaelis–Menten analyses using GraphPad
Prism™ software [8].2.5. Photolabeling of MRP1 by [3H]LTC4
Wild-type and mutant MRP1 membrane proteins were photo-
labeled with [3H]LTC4 essentially as described [20,21]. Brieﬂy, mem-
brane vesicles (50 μg) were incubated with [3H]LTC4 (120 nCi;
200 nM) and 10 mMMgCl2 at room temperature for 30 min and then
frozen in liquid nitrogen. Samples were then alternately irradiated at
302 nm for 1 min and snap-frozen ten times, and the radiolabeled pro-
teins resolved by SDS-PAGE. After ﬁxing and treating the gel with Am-
plify (GE Healthcare, Baie-d'Urfé, QC, Canada), gels were dried and
then exposed to ﬁlm at−70 °C for the times indicated in the ﬁgure leg-
ends. Relative levels of [3H]LTC4 labeling were estimated by densitome-
try as before.
2.6. Photolabeling of MRP1 with 8-azido-[α-32P]ATP
K513Amutant andwild-typeMRP1 from transfected HEK cells were
photolabeled with 8-azido-[α-32P]ATP essentially as described [22].
Brieﬂy, membrane vesicles were dispersed in transport buffer contain-
ing 5 mMMgCl2 and 5 μM 8-azido-[α-32P]ATP. After 5 min incubation
on ice, the sampleswere cross-linked at 302 nm,washed, and then sub-
jected to SDS-PAGE. After drying, the gel was exposed to ﬁlm for 2–4 h.
K513Amutant andwild-typeMRP1membrane proteinswere also incu-
bated in transport buffer containing 5 mM MgCl2, 1 mM freshly
prepared sodium orthovanadate, and 5 μM 8-azido-[α-32P]ATP for 15 -
min at 37 °C to measure orthovanadate-induced trapping of 8-azido-
[α-32P]ADP by MRP1. The reactions were stopped, membrane proteins
washed, and resuspended before cross-linking at 302 nm [22]. Mem-
brane vesicles were then subjected to SDS-PAGE, and after drying, gels
were exposed to ﬁlm for 12–24 h.
2.7. Limited trypsin digestions
HEK or Sf9 insect cell membrane vesicles (2.0 μg per reaction)
enriched for K513A or K516Amutant or wild-typeMRP1 were digested
with trypsin over a range of trypsin:protein ratios for 15 min essentially
as described [9,23]. In the case of HEK293T cellmembranes, trypsin:pro-
tein ratios ranged from 1:5000 to 2.5:1. For insect cell membranes, the
ratios ranged from 1:500 to 1:12.5. Full-length and tryptic fragments
of MRP1 were detected using mAb MRPr1 (diluted 1:5000), mAb
MRPm6 (diluted 1:1000) and mAb 897.2 (diluted 1:5000) as indicated
in the ﬁgure legends and whose epitopes have been mapped to amino
acids 238–247, 1511–1520 and 1318–1388, respectively [11,12]
(Fig. 1A).
3. Results
3.1. K513A and K516Amutants differ in their ability to be rescued by chem-
ical chaperones
The relative effectiveness of glycerol, DMSO, PEG and 4-PBA to res-
cue the processing mutants K513A and K516A was evaluated by com-
paring MRP1 protein levels in lysates prepared from transfected
HEK293T cells treated with or without these chemical chaperones. As
shown in Fig. 2A, all treatments enhanced levels of the K513A mutant
to a similar degree while the same treatments did not signiﬁcantly
alter wild-type MRP1 levels indicating that the rescue is not a result of
transcriptional upregulation. Confocal microscopy conﬁrmed the plas-
ma membrane localization of the rescued K513A mutants indicating
their ability to bypass the quality control mechanisms for protein fold-
ing in the endoplasmic reticulum of HEK cells and to trafﬁc to the plas-
ma membrane (Supplemental Fig. S1).
In contrast to K513A, and consistent with our earlier observations
[9], exposure of K516A transfected cells to glycerol, DMSO, PEG and 4-
PBA only slightly increasedMRP1 levels (Fig. 2B). The panel of chemical
chaperone treatments was then expanded to include the naturally
Fig. 2. Effect of chemical chaperones on relative levels of K513A and K516Amutant MRP1
proteins in HEK293T cells. Shown are representative immunoblots of whole cell lysates
prepared from HEK293T cells transfected with K513A or K516A mutant or wild-type
(WT) MRP1 cDNA expression vectors, with or without exposure to the chemicals indicat-
ed at the top of the blots. Untransfected cells were used as a negative control and MRP1
proteins were detected with mAb QCRL-1. Equal protein loading was conﬁrmed by blot-
ting for α-tubulin. (A) WT-MRP1 (left panel), K513A (right panel); (B) K516A. Similar re-
sults were observed for at least two independent transfections.
Fig. 3. Effect of chemical chaperones on the levels and vesicular transport activity of K513A
mutantMRP1 expressed in HEK cells. (A) Shown is a representative immunoblot of mem-
brane vesicles (1 μg protein per lane) prepared from transfectedHEK293T cells, untreated
(WT-MRP1) or treatedwith the indicated chemicals (K513A) for 48 h. Untransfected cells
were used as a negative control (ctrl).MRP1wasdetectedwithmAbQCRL-1 (upper panel),
and the relative protein levels estimated by densitometry and corrected as needed for any
differences in protein loading as indicated by levels of Na+/K+-ATPase (lower panel). Sim-
ilar values were obtained with vesicles prepared from 2–3 additional independent trans-
fections. (B and C), vesicular transport activity of themembrane vesicles shown in (A)was
measured as ATP-dependent uptake of (B) [3H]E217βG and (C) [3H]LTC4. The results
shown are means (±SD) of triplicate determinations in a single experiment. Similar re-
sults were obtained in at least one additional experimentwith vesicles derived from inde-
pendent transfections.
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have been previously shown to increase levels of processing mutants
of other membrane proteins [24–27]. In addition, given the multiple
intra- and inter-domain interactions that appear to be involved in the
optimal expression ofMRP1 at the plasmamembrane, itmaynot be rea-
sonable to expect a single small molecule to ‘correct’ the conformation
and transport activity of K516A. Consequently, the effect of several com-
binations of chaperones was also explored (Fig. 2B). However, none of
the chemicals, alone or in combination, enhanced K516A levels substan-
tially, leading to the conclusion that the folding defects introduced by
mutation of Lys516 must differ from the defects introduced by mutation
of Lys513, despite the close proximity of the two basic residues in the
coupling helix in CL5.
3.2. Functional characterization of chemically rescued K513AmutantMRP1
proteins
Todeterminewhether or not the chemically rescuedK513Amutants
were transport competent, membrane vesicles were prepared (Fig. 3A)
and vesicular transport activities were measured using the prototypical
organic anion substrates E217βG and LTC4. As shown in Fig. 3, [3H]
E217βG and [3H]LTC4 uptake levels by K513A mutant membrane vesi-
cles prepared from cells treated with 4-PBA or DMSO were comparable
to wild-type MRP1. In contrast, vesicles prepared from glycerol or PEG
treated cells exhibited transport levels that were just 45–50% those of
wild-type MRP1. When E217βG and LTC4 uptake levels by wild-type
MRP1membrane vesicles prepared from cells with or without different
chemical treatments were determined, no signiﬁcant differences were
observed (data not shown). These results indicate that despite restoring
similar levels of the K513A mutant, the chemical chaperones altered
MRP1 function to different extents.3.3. Conformational differences in chemically rescued K513A mutant
proteins
To determine whether the transport properties of the K513A mu-
tants rescued by the different chemical chaperones were associated
with any differences in protein folding, membrane vesicles containing
K513Awere subjected to limited trypsinolysis and tryptic fragments de-
tected by immunoblotting with mAbs directed against epitopes in the
NH2-proximal (mAb MRPr1) and COOH-proximal (mAb MRPm6)
halves of MRP1 (Fig. 4A) [6,29]. As shown in Fig. 4B (left panel), when
trypsin digests of wild-type MRP1 were probed with mAb MRPr1, a
115-kDa fragment (N1, corresponding to MSD0–MSD1–NBD1) was
ﬁrst detected followed by a smaller and broader 30- to 45-kDa (N3,
Fig. 4. Limited trypsin digests of chemically rescued K513Amutants andwild-typeMRP1 expressed in HEK293T cells. (A) Shown is a schematic representation of glycosylatedMRP1with
the sites of initial trypsin cleavage indicated, together with the approximate sizes of the resulting tryptic fragments (N1, N3, C1 and C2), and the epitopes detected by mAbs MRPr1 and
MRPm6. (B)Membrane vesicle proteins (2 μg per lane) from cells expressing wild-typeMRP1 or K513AmutantMRP1 rescuedwith the indicated chemical chaperones were incubated at
37 °C for 15 min with trypsin at different trypsin:protein ratios (range 1:5000 to 2.5:1), and then immunoblotted with (left panel) mAb MRPr1 and (right panel) mAb MRPm6. Trypsin:
protein ratios were (lanes 1–11): no trypsin, 1:5000, 1:1000, 1:500, 1:250, 1:100, 1:50, 1:25, 1:10, 1:1, 2.5:1. Similar results were obtained in a second independent experiment.
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increased as expected [6,8,28]. The four chemically rescued K513A mu-
tants had similar tryptic proﬁles, indicating that the conformation of the
NH2-proximal halves of these mutant proteins were comparable to
wild-type MRP1.To probe for conformational changes in the COOH-proximal halves
of the rescued K513A mutants, the trypsin digests were then
immunoblotted with mAb MRPm6 (Fig. 4B, right panel). Under these
conditions, the wild-type MRP1 digests yielded ﬁrst a larger 75-kDa
fragment (C1, corresponding to MSD2–NBD2) which was then cleaved
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NBD2) as expected [6]. The tryptic proﬁles for the K513A mutants res-
cued by DMSO or 4-PBA were similar to wild-type MRP1, suggesting
that no signiﬁcant conformational changes had occurred in the COOH-
proximal halves of these mutants. In contrast, the tryptic proﬁles of
the glycerol and PEG rescued K513A mutants were substantially differ-
ent. Most notably, the NBD2 (C2) fragments were not detectable in the
glycerol or PEG rescued K513A proteins. These observations indicate
that NBD2 in the glycerol and PEG-rescued K513Amutants is hypersen-
sitive to trypsin suggesting that this region has adopted a more open
(less compact) conformation than is the case in wild-type MRP1.
Conformational changes in NBD2 in the glycerol and PEG rescued
K513A proteins were further corroborated by taking advantage of
two MRP1-speciﬁc conformation-dependent antibodies, mAb QCRL-2
(which recognizes a discontinuous epitope within NBD1) and mAb
QCRL-4 (which recognizes a discontinuous epitope within NBD2) [15].
Serial dilutions of membrane vesicles prepared under non-denaturing
conditions were spotted on a membrane and the dot blots then probed
withmAbQCRL-4 (Fig. 5A, upper panel), andmAbQCRL-2 (Fig. 5B, upper
panel); total proteins were detected by staining with amido black
(Fig. 5C, upper panel); relative signal intensitieswere quantiﬁed by den-
sitometry (Fig. 5, lower panels). As shown in Fig. 5A, the immunoreactiv-
ity of the glycerol and PEG rescued K513A proteins detected by mAb
QCRL-4 was diminished by N50% compared to wild-type MRP1, consis-
tentwith substantial changes in the conformation of NBD2. On the other
hand, there were no differences in the immunoreactivity of themutants
andwild-typeMRP1 detected bymAbQCRL-2 (NBD1) (Fig. 5B). Togeth-
er with the tryptic fragment analyses (Fig. 4), these results indicate that
the transport deﬁciencies of K513A rescued by glycerol or PEG are asso-
ciated with a change to a less compact conformation of NBD2 in MRP1.
3.4. E217βG uptake and [3H]LTC4 photolabeling of glycerol and PEG rescued
K513A MRP1
To further explore the consequences of the conformational changes
detected in the glycerol or PEG rescued K513A proteins, kineticFig. 5. Immunodot blot analyses of the transport-deﬁcient PEG and glycerol rescued K513Amut
non-denaturedmembrane vesicles (corresponding to 0.5, 1 and2 μgprotein) prepared from tra
wild-typeMRP1 (untreated)were spotted on amembrane as described [18] and then probedw
were also stained with amido black to conﬁrm protein loading. A graphic representation of th
K513A (●); PEG-rescued K513A (♦).parameters of E217βG uptake were determined. Consistent with previ-
ous studies, wild-type MRP1 transported [3H]E217βG with a Km and
Vmax of 4.9 μm and 907 pmol mg−1 min−1, respectively [8,19]. The
glycerol and PEG rescued K513A proteins exhibited comparable Km
(E217βG) values of 3.8 and 5.6 μM, respectively, but their Vmax
(E217βG) values were decreased 3 to 4-fold relative to wild-type
MRP1 (230 and 317 pmol mg−1 min−1, respectively). [3H]LTC4
photolabeling of these two rescued K513A proteins and wild-type
MRP1 were also comparable (Fig. 6A). Together, these results indicated
that the reduced transport levels of the PEG and glycerol rescued K513A
mutant were not caused by decreased Km (E217βG) or reduced binding
of LTC4 (at 200 nM).3.5. Photolabeling of glycerol and PEG rescued K513A MRP1 with 8-azido-
[α-32P]ATP and orthovanadate-induced trapping of 8-azido-[α-32P]ADP
Since the transport deﬁciencies of the glycerol- and PEG-rescued
K513A proteins were not associated with differences in Km (E217βG)
or reduced binding of LTC4 (at 200 nM), the nucleotide interactions of
the mutants were examined. First, ATP binding was measured by
photolabeling the proteins with 5 μM 8-azido-[α-32P]ATP under condi-
tions of minimal hydrolysis (4 °C). As shown in Fig. 6B, photolabeling of
the glycerol- and PEG-rescued K513A proteins at this single concentra-
tion of 8-azido-ATP was decreased by 50% and 30%, respectively, com-
pared to wild-type MRP1 (after differences in MRP1 levels were taken
into account). Next, the ‘catalytic’ activity of the rescued mutants was
examined by measuring vanadate-induced trapping of azido-[32P]ADP
under conditions permissive for ATP hydrolysis [22]. As shown in
Fig. 6C, [32P]ADP trapping by glycerol-rescued K513A was 60% lower
than trapping by wild-type MRP1 while trapping by the PEG-rescued
K513A was 40% lower. Thus, the nucleotide interactions of these
mutants have been altered to a degree that correlateswell with their re-
duced transport activities, and are also consistent with the conforma-
tional changes in NBD2 detected by limited trypsinolysis, and the
MRP1-speciﬁc conformation-dependent antibodies.antMRP1with conformation-dependentmAbs against NBD1 and NBD2. Serial dilutions of
nsfectedHEK293T cells expressing K513Amutant (treatedwith glycerol or PEG for 48 h)or
ith conformation-dependentmAbs (A) QCRL-4 (NBD2); and (B) QCRL-2 (NBD1). (C) Blots
e densitometric analyses is shown below each dot blot. WT-MRP1 (■); glycerol-rescued
Fig. 6. [3H]LTC4 photolabeling and azido-[α32P]ATP interactions of transport-deﬁcient PEG
and glycerol rescued K513A mutant proteins expressed in HEK293T cells. (A) Membrane
vesicles (50 μg protein per lane) prepared from transfected HEK293T cells, untreated or
treated with glycerol or PEG for 48 h, were incubated with [3H]LTC4 (200 nM; 120 nCi) at
room temperature for 30 min, irradiated at 302 nm, and then resolved by SDS-PAGE and
processed for ﬂuorography. Shown is a ﬁlm exposure of 3 days at−70 °C (upper panel).
Band intensitiesweredeterminedbydensitometry and relative levels of photolabeling calcu-
lated after correction for any differences inMRP1 levels as detectedwithmAbQCRL-1 (panel
B, lower panel). (B) Membrane vesicles (20 μg protein) from transfected cells, untreated or
treated with glycerol or PEG for 48 h, were incubated with 5 μM 8-azido-[α-32P]ATP on
ice for 5 min in transport buffer containing 5 mM MgCl2. Samples were irradiated at
302 nm and after removal of unincorporated nucleotides, resolved by SDS-PAGE. The gel
was dried and then exposed toﬁlm. Relative band intensitieswere analyzed bydensitometry
and are indicatedby thenumbers below theﬁgures, expressed before and after correcting for
any differences in MRP1 protein levels (lower panel). (C) Vanadate-induced trapping of
azido-ADP was measured by incubating membrane vesicles (20 μg protein) at 37 °C with
8-azido-[α-32P]ATP in the presence (+) or absence (−) of freshly prepared sodium
orthovanadate for 15 min in transport buffer. Samples were irradiated and processed as be-
fore. Similar results were obtained in at least one additional independent experiment.
Fig. 7. Expression and function of K516Amutant MRP1 expressed in insect cells. (A) Rep-
resentative immunoblot of membrane vesicles (1 μg protein per lane) prepared from Sf9
insect cells infected with K516A mutant and wild-type MRP1 recombinant baculoviruses.
Membrane vesicles prepared from cells infected with an empty vector were included as a
negative control (β-gus). MRP1 was detected with mAb QCRL-1 (upper panel) and by
amido black staining (lower panel). (B) [3H]LTC4 transport activity of insect cellmembrane
vesicles enriched for K516A mutant and wild-type MRP1. ATP-dependent uptake of [3H]
LTC4 was measured for 45 s as described in Materials and Methods. The results shown
are means (±SD) of three independent experiments. (C) Photolabeling of insect cell
membrane vesicles with [3H]LTC4. Control insect cell membrane vesicles (β-gus) and
vesicles enriched for K516A mutant and wild-type MRP1 (50 μg protein) were
photolabeled with [3H]LTC4 as described in the legend to Fig. 6. Shown is a ﬁlm exposure
of 7 days at−70 °C (upper panel). Band intensities were determined by densitometry and
relative levels of photolabeling calculated taking into account any differences in MRP1
levels as detected by immunoblotting with mAb QCRL-1 (lower panel).
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Since treatment of HEK293T cells expressing MRP1 K516A with
chemical chaperones alone, and in combination, failed to signiﬁcantlyincrease levels of this mutant protein (Fig. 2C), K516A was cloned into
a baculovirus expression vector and expressed in Sf9 insect cells
which exert less stringent quality control mechanisms during bio-
synthesis of human proteins. As shown in Fig. 7A, this approach
was successful since K516A was expressed at levels comparable to
those of wild-type MRP1 in insect cells. However, the LTC4 transport
activity of the heterologously expressed K516A was reduced by 80%
relative to wild-type MRP1 (Fig. 7B). [3H]LTC4 labeling of the heter-
ologously expressed K516A mutant was also diminished by 90%
(Fig. 7C), indicating the LTC4 substrate binding site of MRP1 had
been compromised.
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In seeking a structural explanation for the reduced substrate binding
of the heterologously expressed K516A mutant, the conformation of
themutant proteinwas probed by limited trypsinolysis followed by im-
munoblotting with mAbs directed against epitopes in the NH2- and
COOH-proximal halves of MRP1 as before (Fig. 8A). Differences in the
wild-type and K516A tryptic fragmentation patterns were detected
with both antibodies. Thus, when probed with mAb MRPr1 (Fig. 8B,
left panel), fragments of unknown identity (50–65 kDa) accumulated
in the case of the K516A mutant but not wild-type MRP1, whereas the
trypsin sensitivity of the full-length, as well as the expected N1 and
N3 (MSD0) fragments, were quite similar. In contrast, when probed
with mAb 897.2 (Fig. 8B, right panel) the tryptic fragmentation of the
K516A mutant was strikingly different from wild-type MRP1. Thus,
the levels of the C1 fragment (MSD2–NBD2) for K516A were substan-
tially reduced relative to wild-type MRP1, despite very similar patterns
of disappearance for the two full-length proteins. Furthermore, the
levels of C2 fragment (NBD2) were also comparable between the
wild-type and K516Amutant suggesting that the trypsin hypersensitiv-
ity of the C1 fragment (MSD2–NBD2) of K516A is mainly due to confor-
mational changes in MSD2.
4. Discussion
The folding and assembly of polytopic multidomain membrane pro-
teins, like the ABC transporters, are governed by complex processes thatFig. 8. Limited trypsindigests of transport-deﬁcient K516AmutantMRP1 in insect cellmembran
trypsin cleavage indicated, together with the approximate sizes of the resulting tryptic fragmen
897.2. (B)Membrane vesicles (2 μg protein) prepared from insect cells expressing transport-deﬁ
at different trypsin:protein ratios (range 1:500 to 1:12.5) and then immunoblotted with (left pa
trypsin, 1:500, 1:230, 1:200, 1:150, 1:100, 1:50, 1:12.5. The boxes highlight signiﬁcant differen
K516A mutant proteins. Similar results were obtained in a second independent experiment.are still far from fully understood. The functional expression of ABC pro-
teins requires not only post- and co-translational intra-domain but also
cooperative inter-domain interactions to ensure their stable native con-
formation(s) are achieved [29–31]. Therefore it is perhaps not surpris-
ing that disease-associated misfolding and processing mutations of
several ABC proteins have been identiﬁed which, despite involving
amino acids in different domains, cause retention of the affected protein
in the ER and often target it for degradation. In some instances, a muta-
tion in the NBD is involved but other domains, including the cytoplas-
mic regions of the MSDs that interface with the NBDs, are also known
to be important [32–35].
It is commonly presumed that there is a relatively high degree of
structural similarity among ABC proteins, and consequently, it would
not be unreasonable to assume that the processes governing their fold-
ing, assembly and membrane trafﬁcking (and the degradation of
misfolded or misassembled mutants) might be also similar. However,
there is growing evidence (including our own) that indicates that this
is not the case, at least not in all the details [29]. For example, for
CFTR, the absence of NBD2 (as in a ΔNBD2-CFTR truncation mutant)
does not affect the processing and trafﬁcking of this chloride channel
[36], while for MRP1, the integrity of the interface between CL5 and
NBD2 interface appears critical for the proper folding and assembly of
this transporter [9]. Whether or not this is related to the fact that
MRP1 (and some of its homologs) contain 5 rather than the typical 4 do-
mains as found in CFTR (and most other ABC proteins) is not known. It
may also be that certain aspects of the co-operative folding and assem-
bly mechanism of each of transporter is unique.es. (A) Shown is a schematic representation of unglycosylatedMRP1with the sites of initial
ts (N1, N3, C1 and C2), and the location of the epitopes detected by mAbMRPr1 and mAb
cient K516Amutant andwild-typeMRP1were incubated at 37 °C for 15 minwith trypsin
nel) mAbMRPr1 and (right panel) mAb 897.2. Trypsin:protein ratios were (lanes 1–8): no
ces between the patterns of the tryptic fragments of the wild-type and transport-deﬁcient
764 S.H. Iram, S.P.C. Cole / Biochimica et Biophysica Acta 1838 (2014) 756–765Low molecular mass chemical chaperones have been used success-
fully for many years to restore expression and plasma membrane traf-
ﬁcking of misfolded proteins including various mutant ABC proteins
[37–39]. Osmolytes like glycerol and PEG are thought to stabilize pro-
teins by increasing protein hydration and reducing the mobility of indi-
vidual protein domains. In doing so, they prevent aggregation of
incompletely folded conformers and promote stabilization by modify-
ing the free energy difference between partially folded proteins and
their more compact native structures [24,40]. Hydrophobic compounds
such as DMSO and 4-PBA can also promote folding of mutant proteins
by reducing the formation of misfolded aggregates and increasing the
pool of folding intermediates. However, they can also have an indirect
effect by altering the levels of intracellular molecular chaperones
[39–42].
In the present study, we have shown that despite the proximity of
the affected amino acids to one another in CL5, the MRP1 processing
mutants K513A and K516A display remarkable differences in their abil-
ity to be functionally rescued by four commonly used chemical chaper-
ones. This implies that although both mutations cause loss of functional
MRP1 at the plasmamembrane, they do so by distinct molecular mech-
anisms. In the case of K513A, levels of the mutant protein could be im-
proved to wild-type MRP1 levels by treatment of cells with all four
chemical chaperones tested (Fig. 2A) [9]. However, only the 4-PBA
and DMSO-rescued K513A mutants displayed organic anion transport
activity comparable to wild-type MRP1.
The reduced transport activity of the glycerol- and PEG-rescued
K513A mutants indicated that the structural defects introduced by the
Lys513 substitution were only partially restored by these two chemical
chaperones. Differences in trypsin fragmentation patterns and immu-
noreactivity with conformation-dependent antibodies revealed that
the NBD2 region of the glycerol and PEG-rescued K513A transport-
deﬁcient MRP1 mutants had adopted a more open, trypsin sensitive
conformation than the same region of wild-typeMRP1 (or the function-
ally intact DMSO or 4-PBA rescued K513A mutants). The kinetic analy-
ses of E217βG transport and the nucleotide labeling results further
indicated that the transport deﬁciencies of the DMSO and PEG-rescued
MRP1 K513A proteins were caused by changes in the binding and hy-
drolysis of ATP. Together, these results allow us to conclude that
Lys513 plays a critical role in the interactions of CL5 (in MSD1) with
NBD2 that are essential for the proper folding and function of the latter
domain in MRP1. Molecular dynamics simulations of the homodimeric
bacterial ABC transporter Sav1866 indicate that it can adopt a structur-
ally asymmetric transition state where one active site is occupied by
ATP in an occluded state while the other site is unoccupied or binds
ATP weakly [43]. The latter unoccupied site was in a more open confor-
mation andmore distant from the cytoplasmic loop region thanwas the
ATP-bound site. These observations support the suggestion that the
K513A mutation in CL5 of MSD1 interferes with the closure of the
NBD2 core subdomain making it less able to form a compact interface
with CL5.
The biochemical properties and mode of action of 4-PBA, glycerol,
DMSO, and PEG are known to vary and it is not clear here why all 4
were equally able to improve K513A levels but glycerol and PEG were
unable to functionally rescue the mutant. Whatever the exact mecha-
nisms, it seems that differential responses to chemical chaperones can
vary according to the misfolded protein in question [24,41]. Thus, in
contrast to MRP1–K513A, glycerol effectively restored the function of
CFTR–ΔF508 while DMSO did not [37,39]. On the other hand, a process-
ing mutant of vasopressin V2 receptor (V2R-V206D) responsible for
congenital nephrogenic diabetes insipidus was rescued by treatment
of cells with DMSO or glycerol but not with TMAO, 4-PBA or by cell
growth at subphysiological temperatures [42].
In contrast to K513A, the K516A processingmutant was remarkably
resistant to rescue by the chemical chaperones tested. It was also
resistant to other osmolytes and chemical chaperones including
proline, apigenin, as well as TMAO, alone or in combination withDMSO or 4-PBA. Thus, it appears that Ala-substitution of Lys516 causes
amore severe folding defect than Ala-substitution of Lys513, and the en-
ergy barrier posed by the defect in the former mutant cannot be over-
come by small molecular mass chaperones, at least in HEK cells. In this
regard, it is of interest that the same charge K513R mutant could be
expressed at levels similar to wild-type MRP1 in HEK cells, while levels
of the analogous K516R mutant were 40% lower [8]. This indicates that
whereas basicity is the most important property of the amino acid side
chain at position 513, both the charge and the volume of the side chain
contribute to the functionality of the amino acid at position 516.
The more stringent requirements on position 516 for MRP1 structure
(and function) are also consistent with the greater conservation of
Lys516 relative to Lys513 across both eukaryotic and prokaryotic se-
quences which makes an evolutionary conserved role for Lys516 more
likely.
Despite the inability of chemical chaperones to rescue K516A ex-
pression in HEK cells, heterologous expression in Sf9 insect cells yielded
levels of the mutant transporter comparable to wild-type MRP1 which
is likely attributable to the lower stringency of the protein quality con-
trol processes in these cells [44–47]. However, despite the robust levels
of K516A mutant achieved in this system, the transport activity of this
mutant was severely diminished. Thus, LTC4 transport levels were just
10% those of wild-type MRP1, and the K516A mutant could no longer
be photolabeled with this substrate. These observations indicated that
the substrate binding pocket of MRP1 had been compromised which
in turn suggested structural differences between the K516A mutant
andwild-typeMRP1 proteins, despite the fact that bothwere expressed
equallywell. Support for this conclusionwas obtained by comparing the
tryptic digest patterns of the two proteins which indicate that the CL5
K516A mutation in MSD1 introduces a change in the COOH-proximal
half of MRP1 (MSD2–NBD2) to a more open, trypsin-sensitive confor-
mation. Since the tryptic fragments of NBD2 (C2) in both wild-type
and K516A were similar, it may be inferred that this conformational
change lies predominantly inMSD2. This is in contrast to theK513Amu-
tant where NBD2 folding was mainly affected.
According to ab initio analyses, both K513A and K516A mutations
are predicted to introduce signiﬁcant rigidity into the tertiary structure
of the coupling helix in CL5 where these Lys residues are found. Both
mutations modify the turn of the helix such that its interface with
NBD2 is altered. However, the orientation of the Lys516 side chain may
be subject to different constraints than Lys513 because the former resi-
due normally relies on bonding interactions with Glu521 to help affect
the turn of the α-helix at Ala519 as the helix makes its way back up to
insert into themembrane (Fig. 1B; Supplemental Fig. 2). This difference
would provide a plausible explanation forwhymutation of Lys516might
be more disruptive to normal domain–domain interactions than muta-
tion of Lys513, which in turn, could explain why the K516A mutant is
more resistant to rescue by chemical chaperones than K513A.
In conclusion, despite the fact that the affected amino acids of the
two processingmutants studied here reside on the same side of the cou-
pling α-helix in CL5, our data indicate that Lys513 and Lys516 participate
in different interdomain interactions during the biosynthesis of MRP1.
Together, our results provide new insights into the complex processes
required for the proper folding, assembly and membrane expression
of MRP1 which may be relevant to other multidomain ABC proteins in-
volved in various genetic and malignant diseases.
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